Interleukin-6 and severe COVID-19: a systematic review and meta-analysis
Helia Mojtabavi1,2, Amene Saghazadeh1,2, Nima Rezaei2,3,4
European Cytokine Network, Vol.31, No.2, pp. 44-49, 2020, DOI:10.1684/ecn.2020.0448
Abstract Background: Evidence links COVID-19 severity to hyper-inflammation. Treatment with tocilizumab, a monoclonal antibody directed against the interleukin-6 (IL-6) receptor, was shown to lead to clinical improvement in patients with severe COVID-19. We, therefore, performed the present systematic review and meta-analysis to investigate whether the circulating levels of IL-6 is a reliable indicator of disease severity among patients affected with COVID-19. Methods: A systematic search was conducted in PubMed, Scopus, Web of Science, and Google Scholar on April 19, 2020. Results: Eleven studies provided data of IL-6 levels in patients with severe to critical COVID-19 (severe)… More >